Navigation

Staxyn

Staxyn (Vardenafil Hydrochloride Orally Disintegrating Tablets) side effects drug center

 

PROFESSIONAL

CONSUMER

SIDE EFFECTS

Staxyn Side Effects Center

Staxyn (vardenafil hydrochloride) Orally Disintegrating Tablets is a muscle relaxer used to treat erectile dysfunction. Common side effects of Staxyn are:

These side effects of Staxyn usually go away after a few hours. Tell your doctor if you experience serious side effects of Staxyn including:

  • an erection that won't go away (priapism)
  • color vision changes, such as seeing a blue tinge to objects or having difficulty telling the difference between the colors blue and green
  • sudden vision loss
  • ringing in your ears or sudden hearing loss
  • chest pain or heavy feeling
  • pain spreading to the arm or shoulder
  • nausea
  • sweating
  • general ill feeling
  • irregular heartbeat
  • swelling in your hands, ankles, or feet
  • shortness of breath
  • lightheadedness or fainting, or
  • seizures (convulsions)

These side effects of Staxyn usually go away after a few hours. Tell your doctor if you experience serious side effects of Staxyn including an erection that won't go away (priapism) or color vision changes, such as:

  • seeing a blue tinge to objects
  • having difficulty telling the difference between the colors blue and green

The recommended dosage of Staxyn is one 10 mg tablet taken 60 minutes before sexual activity. Certain antidepressants, antifungal, antibiotic, heart, and blood pressure medications can interact with Staxyn. Tell your doctor all medications you use. Taking a nitrate medicine with Staxyn can cause a sudden and serious decrease in blood pressure. Contact your doctor or seek medical attention if your erection lasts for more than 4 hours. Staxyn is not indicated for women who are of child bearing years and therefore should not be taken if you are pregnant or breastfeeding.

Our Staxyn (vardenafil hydrochloride) Orally Disintegrating Tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

 

Staxyn Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop taking vardenafil and get emergency medical help if you have:

  • heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating;
  • vision changes or sudden vision loss; or
  • erection is painful or lasts longer than 4 hours (prolonged erection can damage the penis).

Stop using vardenafil and call your doctor at once if you have:

  • ringing in your ears, or sudden hearing loss;
  • irregular heartbeat;
  • swelling in your hands, ankles, or feet;
  • shortness of breath;
  • a light-headed feeling, like you might pass out;
  • penis erection that is painful or lasts 4 hours or longer; or
  • seizure (convulsions).

Common side effects may include:

  • flushing (warmth, redness, or tingly feeling);
  • stuffy nose, sinus pain;
  • headache, dizziness;
  • upset stomach; or
  • back pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Staxyn (Vardenafil Hydrochloride Orally Disintegrating Tablets)

 

Staxyn Professional Information

SIDE EFFECTS

The following serious adverse reactions with the use of STAXYN (vardenafil) are discussed elsewhere in the labeling:

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

STAXYN

Safety of STAXYN was evaluated in two identical multi-national, randomized, double-blind, placebo-controlled trials. In both pivotal studies, enrollment was stratified so that approximately 50% of patients were ≥ 65 years old. Approximately 8% (n=29) were ≥ 75 years old. An integrated analysis of both studies included a total of 355 subjects that received STAXYN compared to 340 subjects that received placebo (mean age was 61.7, range 21.0 to 88.0; 68% White, 5% Black, 6% Asian, 11% Hispanic and 11% Other). The discontinuation rates due to adverse reactions were 1.4% for STAXYN compared to 0.6% for placebo. Table 1 below details the most frequently reported adverse reactions.

Table 1: Adverse drug reactions reported by ≥ 2% of the patients treated with STAXYN and more frequent on drug than placebo in controlled trials

Adverse Drug Reaction STAXYN
(n=355)		 Placebo
(n=340)
Headache 14.4% 1.8%
Flushing 7.6% 0.6%
Nasal Congestion 3.1% 0.3%
Dyspepsia 2.8% 0%
Dizziness 2.3% 0%
Back Pain 2% 0.3%

Adverse drug reactions reported in the STAXYN placebo controlled trials were comparable to the adverse drug reactions reported in earlier vardenafil film-coated tablets placebo controlled trials.

All Vardenafil Studies

Vardenafil film-coated tablets and STAXYN has been administered to over 17,000 men (mean age 54.5, range 18 - 89 years; 70% White, 5% Black, 13% Asian, 4% Hispanic and 8% Other) during controlled and uncontrolled clinical trials worldwide. The number of patients treated for 6 months or longer was 3357, and 1350 patients were treated for at least 1 year.

In the placebo-controlled clinical trials for vardenafil film-coated tablets and STAXYN, the discontinuation rate due to adverse events was 1.9% for vardenafil compared to 0.8% for placebo. Placebo-controlled trials suggested a dose effect in the incidence of some adverse reactions (for example, dizziness, headache, flushing, dyspepsia, nausea, nasal congestion) over the 5 mg, 10 mg, and 20 mg doses of vardenafil film-coated tablets.

The following section identifies additional, less frequent adverse reactions (<2%) reported during the clinical development of vardenafil film-coated tablets and STAXYN. Excluded from this list are those adverse reactions that are infrequent and minor, those events that may be commonly observed in the absence of drug therapy, and those events that are not reasonably associated with the drug:

Body as a whole: allergic edema and angioedema, feeling unwell, allergic reactions, chest pain Auditory: tinnitus, vertigo

Cardiovascular: palpitation, tachycardia, angina pectoris, myocardial infarction, ventricular tachyarrhythmias, hypotension

Digestive: nausea, gastrointestinal and abdominal pain, dry mouth, diarrhea, gastroesophageal reflux disease, gastritis, vomiting, increase in transaminases

Musculoskeletal: increase in creatine phosphokinase (CPK), increased muscle tone and cramping, myalgia

Nervous: paresthesia and dysesthesia, somnolence, sleep disorder, syncope, amnesia, seizure

Respiratory: dyspnea, sinus congestion

Skin and appendages: erythema, rash

Ophthalmologic: visual disturbance, ocular hyperemia, visual color distortions, eye pain and eye discomfort, photophobia, increase in intraocular pressure, conjunctivitis

Urogenital: increase in erection, priapism

Postmarketing Experience

The following adverse reactions have been identified during post approval use of vardenafil in the film-coated tablet formulation. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.

Ophthalmologic

Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely postmarketing in temporal association with the use of PDE5 inhibitors, including vardenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient's underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors [see WARNINGS AND PRECAUTIONS and PATIENT INFORMATION].

Visual disturbances including vision loss (temporary or permanent), such as visual field defect, retinal vein occlusion, and reduced visual acuity, have also been reported rarely in postmarketing experience. It is not possible to determine whether these events are related directly to the use of vardenafil.

Neurologic

Seizure, seizure recurrence and transient global amnesia have been reported postmarketing in temporal association with vardenafil.

Otologic

Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including vardenafil. In some cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of vardenafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see PATIENT INFORMATION].

Read the entire FDA prescribing information for Staxyn (Vardenafil Hydrochloride Orally Disintegrating Tablets)

&Copy; Staxyn Patient Information is supplied by Cerner Multum, Inc. and Staxyn Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.